Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
| Autor: | Czuczman, M.S. *, Leonard, J.P., Jung, S., Johnson, J.L., Hsi, E.D., Byrd, J.C., Cheson, B.D. |
|---|---|
| Zdroj: | In Annals of Oncology September 2012 23(9):2356-2362 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|